Paul Rennie, BSc, MBM, MS
Chief Operating Officer
Mr. Rennie has over 25 years experience in marketing and business development within the Australian biomedical and pharmaceutical industry. He was formerly Director of Business Development for Soltec, a wholly owned subsidiary of F H Faulding & Co., Ltd, with focus on developing improved pharmaceutical drug delivery systems.
Previously, as Business Development Manager for the Biosciences Division of Bonlac, he led the commercialisation strategies and licensing negotiations between Bonlac and multinational global oral care and health care/nutritional companies, including Johnson & Johnson, Procter & Gamble, and SmithKlineBeecham, and successfully concluded licensing of Bonlac’s CPP-ACP technology to Warner Lambert.
Between 1990-1994 he held various positions with the global pharmaceutical company Merck Ltd, where as National Sales and Marketing Manager he was responsible for Australia-wide sales of pharmaceuticals, analytical reagents, environmental monitoring products, and scientific research products. In this capacity, Mr. Rennie implemented a new strategic plan which contributed to transforming Merck Australia from having a loss in 1993 to record sales and profits in 1996.